Vision Research & Clinical Studies
Advancing the Future of Eye Care
At Gulf Coast Eye Institute, we are dedicated to advancing ophthalmic care through clinical research and innovation. Our research team participates in studies evaluating new treatments, technologies, and approaches to eye care, helping improve outcomes for patients today and in the future.
Working closely with physicians, study sponsors, and participants, our experienced research staff ensures every study is conducted with a strong focus on safety, accuracy, and patient care. Through ongoing research efforts, we help bring promising new advancements in vision care to the communities we serve.
Interested in Participating?
Contact Gulf Coast Eye Institute to learn more about current clinical research opportunities and whether a study may be right for you.
LIST OF TRIALS ACTIVELY RECRUITING
NCT05966493: NEXPEDE-1
A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects with PCED (NEXPEDE-1) ClinicalTrials.gov ID NCT05966493:
NCX-470-02: Mont Blanc
A Phase 3, Randomized, Adaptive Dose-Selection, Multi-Regional, Double-Masked, Parallel-Group, 3-Month Trial Evaluating the Safety and Efficacy of NCX 470 vs. Latanoprost 0.005% in Subjects with Open-Angle Glaucoma or Ocular Hypertension (Mont Blanc)
NCX-470-03: Denali
A Phase 3, Randomized, Multi-Regional, Double-Masked, Parallel-Group Trial Evaluating the Safety and Efficacy of NCX 470 0.1% vs. Latanoprost 0.005% in Subjects with Open-Angle Glaucoma or Ocular Hypertension (Denali)
BTQ-1901-1902-201: Betaliq
A Randomized, Multicenter, Observer-Masked Study to Compare the Safety and Efficacy of BTQ-1901-A, BTQ-1901-B, and BTQ-1902 to Timolol 0.5% in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension
Alcon | ILR431B-P001
Post Approval Study of the AcrySof® IQ ReSTOR® Toric IOLs
Biorasi CLR_16_33
A Randomized, Multi-Center, Investigator-Masked, Parallel Group,
Equivalence Study of Once Daily Brimonidine Tartrate Ophthalmic
Suspension Compared with Three Times Daily Alphagan® P in Subjectswith Open Angle Glaucoma or Ocular Hypertension.
